Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04853914
Other study ID # HIFU/F/20.09
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 13, 2021
Est. completion date June 2022

Study information

Verified date October 2021
Source EDAP TMS S.A.
Contact Claire Jossan
Phone 04 72 15 31 50
Email Affaires-cliniques@edap-tms.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Prostate adenoma or benign prostatic hypertrophy (BPH) is a benign disease of the prostate gland. It results in an increase in the volume of the prostate area located in contact with the urethra. Compression of the prostatic urethra by the adenoma can cause lower urinary tract disorders. The classic treatments in case of failure of medical treatment are endoscopic resection of the prostate and adenomectomy, but these techniques are characterized by a significant hemorrhagic risk that may require transfusions and prolonged hospitalization. Minimally invasive treatments with low morbidity have been developed to overcome these drawbacks. They allow to propose a therapeutic solution adapted to patients: not tolerating their medical treatment, wishing to keep antegrade ejaculation, elderly and/or frail, at risk of bleeding, wishing an ambulatory treatment, refusing the conventional surgical techniques. The Focal One® device was developed to treat prostate cancer using ultrasound energy. This energy is delivered through a probe placed in your rectum. Connected to this probe, an ultrasound machine will allow your doctor to see precisely which part of your prostate is being treated. By heating the prostate tissue to a very high temperature in one treatment session, the energy delivered will then destroy the tissue. Ultrasound guidance coupled with the localized nature of the treatment allows the targeted area to be treated while respecting the prostate tissue and structures adjacent to the prostate and thus reducing side effects. Treatment of prostate adenoma with HIFU would allow for localized destruction to reduce prostate volume. The reduction of the compression of the prostatic urethra thus obtained would allow an improvement of the urinary disorders. The treatment is performed transrectally under real-time ultrasound control, which allows the adjacent structures to be respected, thus preserving antegrade ejaculation and limiting the side effects.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date June 2022
Est. primary completion date June 2022
Accepts healthy volunteers No
Gender Male
Age group 50 Years and older
Eligibility Inclusion Criteria: - Over 50 years of age, - BPH greater than 30 cc confirmed by endorectal ultrasound - IPSS score > 7, Qol-IPSS > 2, IIEF-5 score > 11 - Qmax < 15 ml/s or urinary retention (in indwelling catheter, self-catheterization, or with an RPM > 300 cc). - In failure or intolerance of drug treatment(s) for BPH - negative cytobacteriological examination of the urine Exclusion Criteria: - Prostate volume > 80 ml - Presence of a median lobe - Men allergic to latex - Contraindication to the insertion of a transrectal HIFU probe: rectal fistula, anal or rectal fibrosis, or other abnormalities - History of prostate surgery - History of prostate radiation therapy - History of bladder cancer - Current anti-coagulant treatment with a stopping window that cannot exceed 48 hours at the time of the HIFU procedure - Presence of a urinary tract fistula - History of inflammatory bowel disease - Ongoing urogenital infection - Neurological bladder pathology - History of urethral stenosis - Confirmed or suspected prostate cancer - Contraindication to surgery (including anesthesia) - Contraindication to pelvic MRI - Presence of metallic implants or stents in the urethra - Presence of prostatic calcification whose location interferes with HIFU treatment - Patients with renal failure with a GFR <35ml/min

Study Design


Intervention

Device:
HIFU treatment
HIFU treatment of Benign Prostatic Hyperplasia

Locations

Country Name City State
France Hopital Edouard Herriot, service d'urologie Lyon

Sponsors (1)

Lead Sponsor Collaborator
EDAP TMS S.A.

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary The safety of HIFU treatment will be assessed by analyzing adverse events (serious and non-serious) reported during follow-up. 3 months
Secondary Evaluation of treatment performance by maximum urine output (Qmax) 1 and 3 months
Secondary Evaluation of treatment performance by residual post-void volume (RPM) 1 and 3 months
Secondary Evaluation of voiding symptomatology with IPSS questionnaire 1 and 3 months
Secondary Evaluation of quality of urinary life with Qol-IPSS score 1 and 3 months
Secondary Evaluation of quality of erection with IIEF-5 questionnaire 1 and 3 months
Secondary Evaluation of ejaculation quality with MSHQ-SF questionnaire 1 and 3 months
Secondary Evaluation of continence with ICIQ-SF questionnaire 1 and 3 months
Secondary Evaluation of the global impression of improvement scale with PGI-1 questionnaire 1 and 3 months
Secondary Evaluation of the change in the PSA rate 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Completed NCT04831476 - Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)